CHEK1 and ovarian carcinoma: Furthermore, ATR participates in the HR pathway by phosphorylating and regulating BRCA1 and other important proteins.53, 54 The depletion of ATR but not CHK1 using siRNAs or small molecular inhibitors has been demonstrated to sensitize ovarian cancer cells (including HR‐proficient cells) to PARP inhibitors.